Table 1.
Selected miRNA candidates that might be clinically relevant in the management of PanCa
| miRNA | Status | Role | Targets | Significance | Ref. |
|---|---|---|---|---|---|
| miR-21 | ↑ | O | EGFR, HER2/neu, PDCD4, Bcl2, PTEN, TIMP2, TIMP3 | Postresection short DFS/worse OS Gem chemoresistance Biomarker (Dtc: plasma, serum, feces) | (11, 27, 28, 42) |
| miR-155 | ↑ | O | TP53INP1 | Postresection poor OS and prognosis | (8, 9) |
| miR-196a-2; miR-196b | ↑ | O | HOXB8, ANXA1, HMGA2 | Postresection Biomarker (Dtc: plasma) | (19, 43–45) |
| miR-222/221 | ↑ | O | CDKN1B (p27), PUMA, PTEN, Bim | Postresection poor OS and prognosis Gem chemo-resistance Biomarker (Dtc: plasma) | (8, 19, 28, 42) |
| miR-210 | ↑ | O | HOXA1, FGFRL1, HOXA9, COX10, E2F3, RAD52, ACVR1B, MNT | Postresection poor OS Biomarker (Dtc: plasma, feces) | (8, 19, 42) |
| miR 10a/b | ↑ | O | HOXB8 HOXA1 |
poor OS; Gem chemo-resistance | (15, 16) |
| miR-375 | ↑ | O | PDK1, 14-3-3zeta | Biomarker (Dtc: plasma, feces) | (19, 22, 46) |
| miR-301a | ↑ | O | Bim, NKRF | Proliferation and metastasis | (17, 18) |
| miR-200a/b/c | ↓ | TS | EP300 | Postresection high expression improved OS Gem chemosensitivity | (19, 21, 37, 47) |
| miR-34a | ↓ | TS | Bcl-2 | Improved OS after treatment, marker for Gem chemosensitivity | (35) |
| Let-7 | ↓ | TS | E2F2, c-Myc, KRAS, MAPK | Enhances chemosensitivity | (37) |
| miR-34b | ↓ | TS | Smad3 | Reduces invasion/metastasis | (48) |
| miR-96 | ↓ | TS | KRAS, AKT | Inhibits tumor growth and invasion | (24) |
DFS: Disease free survival; OS: Overall survival; Gem: Gemcitabine; Dtc: Detection